CHAPEL HILL, N.C., Sept. 17 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the UBS Global Life Sciences Conference at 9:00 a.m. EDT, September 20, 2010, at the Grand Hyatt New York in New York City. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ (sodium fusidate, formerly CEM-102) for the oral treatment of gram positive pathogens including MRSA.
About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.firstname.lastname@example.org Tony Russo, Ph.D.Russo Partners, LLC(212) 845-4251Tony.email@example.com
|SOURCE Cempra Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved